CN106267134A - 一种消炎镇痛中药组合物及其制备方法 - Google Patents
一种消炎镇痛中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN106267134A CN106267134A CN201610975919.1A CN201610975919A CN106267134A CN 106267134 A CN106267134 A CN 106267134A CN 201610975919 A CN201610975919 A CN 201610975919A CN 106267134 A CN106267134 A CN 106267134A
- Authority
- CN
- China
- Prior art keywords
- extract
- chinese medicine
- medicine composition
- preparation
- inflammatory analgesic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 66
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 230000000202 analgesic effect Effects 0.000 title claims abstract description 40
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- 239000000284 extract Substances 0.000 claims abstract description 116
- 239000002674 ointment Substances 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000007788 liquid Substances 0.000 claims abstract description 8
- 230000033228 biological regulation Effects 0.000 claims abstract description 5
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000003974 emollient agent Substances 0.000 claims abstract description 5
- 235000014593 oils and fats Nutrition 0.000 claims abstract description 5
- 239000003755 preservative agent Substances 0.000 claims abstract description 5
- 230000002335 preservative effect Effects 0.000 claims abstract description 5
- 239000002562 thickening agent Substances 0.000 claims abstract description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 7
- 238000010828 elution Methods 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 5
- 239000011347 resin Substances 0.000 claims description 5
- 229920005989 resin Polymers 0.000 claims description 5
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 4
- 235000008397 ginger Nutrition 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 3
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical group CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- -1 carries out reflux Substances 0.000 claims description 2
- 229940100554 isononyl isononanoate Drugs 0.000 claims description 2
- 241000234314 Zingiber Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 25
- 230000014509 gene expression Effects 0.000 abstract description 10
- 210000003205 muscle Anatomy 0.000 abstract description 8
- 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 abstract description 5
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 230000000474 nursing effect Effects 0.000 abstract description 2
- 102100027456 Cytochrome c oxidase subunit 2 Human genes 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 description 21
- 230000036407 pain Effects 0.000 description 20
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 18
- 206010061218 Inflammation Diseases 0.000 description 18
- 230000004054 inflammatory process Effects 0.000 description 18
- 238000012360 testing method Methods 0.000 description 13
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 235000010418 carrageenan Nutrition 0.000 description 10
- 229920001525 carrageenan Polymers 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 210000002683 foot Anatomy 0.000 description 9
- 230000008961 swelling Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 230000008595 infiltration Effects 0.000 description 8
- 238000001764 infiltration Methods 0.000 description 8
- 210000004969 inflammatory cell Anatomy 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 102000003945 NF-kappa B Human genes 0.000 description 7
- 108010057466 NF-kappa B Proteins 0.000 description 7
- 229960001193 diclofenac sodium Drugs 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000700199 Cavia porcellus Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 102000003777 Interleukin-1 beta Human genes 0.000 description 4
- 108090000193 Interleukin-1 beta Proteins 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 208000003643 Callosities Diseases 0.000 description 3
- 206010020649 Hyperkeratosis Diseases 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 244000273928 Zingiber officinale Species 0.000 description 3
- BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229940015826 dihydroxyaluminum aminoacetate Drugs 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 239000012567 medical material Substances 0.000 description 3
- 210000000929 nociceptor Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 238000007492 two-way ANOVA Methods 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 229920003081 Povidone K 30 Polymers 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 108010084652 homeobox protein PITX1 Proteins 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 210000003371 toe Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 240000005099 Cercis occidentalis Species 0.000 description 1
- 235000006228 Cercis occidentalis Nutrition 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010025252 Kassinin Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010050031 Muscle strain Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241001604597 Pyrestini Species 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000007613 Shoulder Pain Diseases 0.000 description 1
- 241000117268 Sigesbeckia glabrescens Species 0.000 description 1
- 240000003801 Sigesbeckia orientalis Species 0.000 description 1
- 235000003407 Sigesbeckia orientalis Nutrition 0.000 description 1
- 241000123886 Sigesbeckia pubescens Species 0.000 description 1
- 241000219784 Sophora Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 108091008700 nociceptors Proteins 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000037324 pain perception Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000009306 yunnan baiyao Substances 0.000 description 1
- 239000001841 zingiber officinale Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Abstract
本发明涉及一种消炎镇痛中药组合物,所述消炎镇痛中药组合物包括如下组分及其重量比:豨莶提取物:干姜提取物:苦参提取物=1~4:2~5:6~10;本发明还涉及含有所述消炎镇痛中药组合物的制备方法,包括如下步骤:制备豨莶提取物、干姜提取物、苦参提取物;将水、增稠剂、液体防腐剂混合得到A相;在丁二醇中添加豨莶提取物、干姜提取物、苦参提取物得到B相;将B相溶于A相,再加入润肤剂和油脂,最后加入PH调节剂调节PH值,充分搅拌,制得膏剂。与现有技术相比,本发明所述的中药组合物,配伍精当,见效较快,安全无毒副作用,能显著下调模型个体IL‑1β、TNF‑α、COX2和NF‑κB的表达,具有显著的消炎镇痛功效,起到肌肉和关节护理的作用。
Description
技术领域
本发明涉及中医药技术领域,具体涉及一种消炎镇痛中药组合物,并涉及该中药组合物的制备方法。
背景技术
肌肉酸痛是代谢废物积累、肌肉痉挛、结缔组织损伤等生理变化的后果,和炎症反应密切相关。骨骼和关节由于机械损伤,软骨细胞修复失调,细胞外环境改变,也会发生疼痛,也主要和炎症反应相关(炎症基因的表达和炎症介质的释放)。
关于疼痛的产生,炎症假说认为疼痛是由机械性损伤所导致的一系列炎症反应,其中钙离子起到了触发作用。炎症细胞及其释放的炎症介质有强烈的致炎致痛作用:机体系统循环中白细胞增多,IL-1、IL-6浓度增加。由于吞噬细胞的活动和组织坏死,使IV类游离神经末梢的间质中堆积了组织胺、激肽和钾,同时水肿使压力增加,局部温度升高,刺激了伤害感受器,引起了疼痛感觉。
肌肉和关节由于牵拉力的作用,炎症反应和分解代谢加强,重度的机械性牵拉可促进NF-κB的表达,促使炎症基因过表达。运动后使肌肉中环氧酶-2(COX-2)表达上调,进而神经生长因子(NGF)和神经胶质细胞株源性的神经营养因子(GDNF)表达上调,它们可以敏化痛觉感受器,导致机械性痛敏。抑制急性疼痛、阻碍炎症的蔓延,是缓解疼痛感受的重要前提,局部炎症刺激产生的致炎因子,如IL-1、IL-6、TNF-α等在疼痛的产生和维持阶段发挥重要作用,而IL-1、IL-6、TNF-α的合成,以及其作用的发挥都与核因子-kappa B(NF-κB)密切相关。
中国专利CN 103961594A公开了一种治疗足跟痛的药膏,其组成原料为羌活、紫荆皮、透骨草、淫羊藿、草乌头、何首乌、苦参等成分,具有活血、消肿、止痛的功效,具有见效快、疗效确切、治愈率高、安全方便等特点。但其中含有的草乌头含有毒性成分生物碱,若处理不当,可能对使用者产生危害。
中国专利CN 105169314A涉及一种以植物中草药为原料制成治疗肩颈僵硬的中药,由姜、肉桂、当归、黄柏、大泡通等11种中药成分组成,经多年临床试验总结而得,特别针对长期坐姿僵硬引起的电脑病患者;针对肩颈部位的酸痛问题,利用姜、肉桂、大泡通作为主要,辅以精油调和促进吸收,起到活血化瘀、散瘀止痛的功效。但此中药组方药味过多致所含化学成分复杂,多种化学成分之间的相互牵制肯定会削弱药物的效力,共存成分过多也会影响溶出;加之溶剂精油也含有多种化学成分,易造成皮肤敏感。
中国专利CN 1216634C涉及一种以纯天然植物药材为主要药用成分的具有祛风除湿、散寒通络、抗炎、消肿及镇痛功效的药物组合物。所述药物组合物由功劳木、飞龙掌血、血满草、海桐皮、豨莶草、火把花根、倒扣草组成。主要功能主治为祛风除湿、散寒通络,用于风寒痹症,证见:关节疼痛,屈伸不利,腰肌劳损、外伤性腰腿痛。功效测试采用角叉菜胶致大鼠足跖肿胀模型,结果发现2g/kg(相当于临床用量的10倍)的该药物组合物及0.8g/kg的云南白药均非常显著的减少左右足体积差值,作用可持续6h以上,具有非常明显的抗炎抗水肿作用,并具有一定的量效关系。而采用小鼠热板法模型考察镇痛作用时,2g/kg的该药物组合物能明显延长舔后足时间,药效可持续120min,也表现出非常明显的镇痛作用,并具有一定的量效关系。但此中药组合物组分较多,各组分之间互相制约药效,且其用量较大,成本较高。
发明内容
本发明的主要目的在于克服现有技术中的缺陷,提供一种消炎镇痛中药组合物,其用于肌肉、骨骼的消炎镇痛,能显著减少福尔马林疼痛模型小鼠舔后足的次数,具有镇痛作用;同时显著下调模型个体IL-1β、TNF-α、COX2和NF-κB的表达,抑制炎症细胞的浸润,缓解局部炎症。
为实现上述目的,本发明采用如下技术方案:
一方面,本发明一种消炎镇痛中药组合物,包括豨莶提取物、干姜提取物和苦参提取物,所述豨莶提取物、干姜提取物和苦参提取物的重量比为1~4:2~5:6~10。
另一方面,本发明还提供一种消炎镇痛中药组合物的制备方法,包括如下步骤:
步骤一、分别制备豨莶提取物、干姜提取物、苦参提取物;
步骤二、将水、增稠剂、液体防腐剂混合得到A相;
步骤三、在丁二醇中添加豨莶提取物、干姜提取物、苦参提取物得到B相;
步骤四、将步骤三所述的B相溶于步骤二所述的A相,得到混合相C;
步骤五、在步骤四所述的混合相C中加入润肤剂和油脂,得到混合相D;
步骤六、在步骤五所述的混合相D中加入PH调节剂调节PH值,充分搅拌,制得中药组合物的膏剂。
优选的,所述中药组合物的膏剂中:以重量计,豨莶提取物的含量为0.1%~0.4%,干姜提取物的含量为0.2%~0.5%,苦参提取的含量为0.6%~1.0%。
优选的,所述豨莶提取物的制备方法如下:将豨莶草粉碎、过筛,加入溶剂进行水浴提取,提取液静置过夜;对提取液进行抽滤,将所得的滤液进行富集纯化、旋蒸干燥,获得豨莶提取物。
优选的,所述豨莶提取物的制备方法中过筛精度为8目~14目,更优选10目筛。
优选的,所述豨莶提取物的制备方法中溶剂的量为10L/kg豨莶草。
优选的,所述豨莶提取物的制备方法中溶剂为水,水浴提取次数为2次,水浴温度为50℃,提取液采用乙醇洗脱、过树脂柱进行富集纯化。
优选的,所述豨莶提取物的制备方法中的滤液富集纯化的步骤如下:滤液直接通入树脂,采用(1)10%、20%、30%、95%乙醇洗脱,每个梯度洗脱3个柱体积;(2)采用30%洗脱,95%富集,各洗脱3个柱体积。
优选的,所述干姜提取物的制备方法如下:干姜片粉碎、过筛,加入70%乙醇水溶液进行超声提取,对提取液进行抽滤,将所得的滤液干燥,获得干姜提取物。
优选的,所述干姜提取物的制备方法中过筛精度为8目~14目,更优选10目筛。
优选的,所述干姜提取物的制备方法中70%乙醇水溶液的量为250L/kg干姜。
优选的,所述所述干姜提取物的制备方法中超声提取的时间为10~30min,更优选15min。
优选的,所述苦参提取物的制备方法如下:苦参粉碎、过筛,加入水,进行回流提取;对提取液进行抽滤,将所得的滤液干燥,获得苦参提取物。
优选的,所述苦参提取物的制备方法中过筛精度为8目~14目,更优选10目筛。
优选的,所述苦参提取物的制备方法中水的量为8kg/kg苦参。
优选的,所述苦参提取物的制备方法中回流提取的次数为3次,每次回流提取的时间为3小时。
优选的,所述增稠剂为卡波姆U21,所述液体防腐剂为PE9010,所述润肤剂为ININ(异壬酸异壬酯),所述油脂为GTCC,所述PH调节剂为1%氢氧化钠,所述PH值为5.5~6.5。
优选的,所述膏剂的步骤二~步骤六的具体操作步骤如下:将350~450g水、300~400g 2%U21、3~8g PE9010混合得到A相,60~100g丁二醇中添加1g~4g豨莶提取物、2g~5g干姜提取物、6g~10g苦参提取物,组成B相,B相溶于A相后,再加入10~30g ININ、40~80g GTCC,最后加入1%氢氧化钠调节pH值到5.5~6.5范围内,充分搅拌,即得膏剂。
优选的,所述PH值为6.05~6.11。
最后,本发明提供了一种消炎镇痛中药组合物在药品和日化产品中的应用。
优选的,所述消炎镇痛中药组合物可选择合适的辅料,按常规方法制得所需药物剂型,如颗粒剂、口服液、胶囊剂、片剂、丸剂、糖浆剂、袋泡茶、涂敷剂等。
优选的,所述消炎镇痛中药组合物可制备成巴布剂。
优选的,所述巴布剂的制备过程如下:制备含有消炎镇痛中药组合物的膏剂;将膏剂、增粘剂、甘羟铝、甘油、酒石酸、聚维酮混合搅拌;将混合物置于涂布机的加料槽中,以低速涂布于背衬材料上,制得巴布剂。
优选的,所述涂布速度为1~3m/h,更优选2m/h。
优选的,所述增粘剂为ViscomateTM NP-700(Ashland)。
优选的,所述巴布剂的制备过程中各组分的质量如下:120~180g膏剂、40~70g增粘剂、1~5g甘羟铝、200~400g甘油、1~3g酒石酸、10~30g聚维酮K90。
豨莶,又名豨莶草,是菊科植物豨莶Siegesbeckia orientalis L.、腺梗豨莶Siegesbeckia pubescens Makino或毛梗豨莶草Siegesbeckia glabrescens Makino的干燥地上部分。用于风湿痹痛、筋骨不利、腰膝无力、疟疾、急性肝炎、高血压病、疔疮肿毒、外伤出血。
姜,又名生姜,为姜科植物姜Zingiber officinale Rosc.的新鲜根茎。解表散寒,温中止呕,化痰止咳。用于风寒感冒,胃寒呕吐,寒痰咳嗽。中医认为,生姜甘辛而温,具有散寒发汗、温胃止吐、杀菌镇痛、抗炎的功效,能舒张毛细血管,增强血液循环,有助于清除炎症介质和代谢废物,缓解局部疼痛。
苦参为豆科植物苦参Sophora flavescents Ait.的干燥根,具有清热燥湿、杀虫止痒、通利小便和抗炎抗肿瘤等功效。现代研究表明,苦参具有抑菌、抗炎、抗心律失常、抗肝纤维化、抗肝损伤、抗肿瘤、免疫调节等广泛的药理作用,其中的五种生物碱均有镇痛作用。
与现有技术相比,本发明具有以下有益效果:
本发明针对缺乏用药精专、合理配伍的用于肌肉、骨骼消炎镇痛的中药组合,提出基于豨莶、姜和苦参的中药组合物,其具有显著的消炎镇痛功效,能显著减少福尔马林疼痛模型小鼠舔后足的次数,具有镇痛作用;同时显著下调模型个体IL-1β、TNF-α、COX2和NF-κB的表达,抑制炎症细胞的浸润,缓解局部炎症,减少对痛觉感受器的直接刺激,从而达到直接的镇痛效果,起到肌肉和关节护理的作用;
本发明所述的豨莶、姜和苦参的中药组合物,组方严谨、配伍精当,虽寥寥几味却药力专注,相互制约力小而见效较快。药物中的主要化学成分组成简单、清晰,作用直接,避免了药味过多、配伍不当,所含化学成分之间因复杂的反应而降低处方疗效的情况。精炼的药物配比,比传统的中药大处方毒性更低,安全无毒副作用,且降低不良反应几率。
具体实施方式
下面结合实施例,对本发明的具体实施方式作进一步描述。以下实施例仅用于更加清楚地说明本发明的技术方案,而不能以此来限制本发明的保护范围。
实施例1
制备豨莶提取物:豨莶草粉碎后过10目筛,称取5kg,于50℃水浴提取两遍,每次溶剂都为50L水,提取液静置过夜,抽滤。水提取液过大孔树脂富集纯化提取物,滤液直接上直径17cm、柱体积26L的D101树脂,采用(1)10%、20%、30%、95%乙醇洗脱,每个梯度洗脱3个柱体积,每个柱体积26L;(2)采用30%洗脱,95%富集,各洗脱3个柱体积,每个柱体积26L。将上样流出液旋蒸、干燥后,得到豨莶提取物共29.89g。
实施例2
制备干姜提取物:干姜片粉碎后过10目筛,称取3kg,于750L体积的70%乙醇水中超声提取15min,滤液干燥后得到干姜提取物共121.8g。
实施例3
制备苦参提取物:苦参粉碎后过10目筛,称取3kg,加入药材8倍量于药材的水,回流提取2h,提取3次,合并提取液,抽滤,蒸干后得苦参提取物共241.8g。
实施例4
制备消炎镇痛中药组合物:将389g水、350g 2%U21、5g PE9010混合得到A相,80g丁二醇中添加1g~4g豨莶提取物、2g~5g干姜提取物、6g~10g苦参提取物,组成B相,B相溶于A相后,再加入20g ININ、60g GTCC,最后加入1%氢氧化钠调节pH值到6.05~6.11范围内,充分搅拌,即得中药组合物膏剂。其中,豨莶提取物的含量为0.1%~0.4%,干姜提取物的含量为0.2%~0.5%,苦参提取物的含量为0.6%~1.0%。
实施例5
制备含消炎镇痛中药组合物的巴布剂:将150g实施例4所得的中药组合物的膏剂、55g ViscomateTM NP-700(Ashland)、2.5g甘羟铝、300g甘油、1.5g酒石酸、20g聚维酮K90搅拌后,将混合物置于涂布机的加料槽中,以低速(约2m/hour)涂布,即得巴布剂。
实施例6
采用小鼠福尔马林试验分别研究实施例1~实施例3以及实施例4所述的豨莶提取物组、干姜提取物组、苦参提取物以及中药组合物膏剂的镇痛作用。
试验采用雄性ICR小鼠,体重250-300g,随机分成8组,每组10只,
试验组包括模型组、双氯芬酸钠0.5g/kg组、0.1%豨莶提取物组、0.2%干姜提取物组、0.6%苦参提取物组、低剂量组(1g/kg)、中剂量组(2g/kg)、高剂量组(4g/kg);
其中,0.1%豨莶提取物组是指按照实施例4所述的步骤,不添加干姜提取物和苦参提取物,制备的中药组合物膏剂,豨莶提取物的重量份数为0.1%;
其中,0.2%干姜提取物组是指按照实施例4所述的步骤,不添加豨莶提取物和苦参提取物,制备的中药组合物膏剂,干姜提取物的重量份数为0.2%;
其中,0.6%苦参提取物组是指按照实施例4所述的步骤,不添加豨莶提取物和干姜提取物,制备的中药组合物膏剂,干姜提取物的重量份数为0.6%;
其中,低剂量组(1g/kg)、中剂量组(2g/kg)、高剂量组(4g/kg)采用的为实施例4制备的中药组合物膏剂。
实验开始前,将外用受试物和双氯芬酸钠涂抹于小鼠左后足,按摩1min帮助吸收,1小时后相同足趾皮下注射2.5%甲醛溶液0.02ml。模型组只做按摩不涂药,1小时后相同足趾皮下注射2.5%甲醛溶液0.02ml。分别记录注射后0-5min(疼痛早期)、注射后20-30min(疼痛后期)两个时期内动物舔抓足掌的时间(单位:秒),以此指示疼痛反应。并分别计算疼痛早期和疼痛晚期的疼痛抑制率:疼痛抑制率(%)=(1-实验组舔舐时间/对照组舔舐时间)×100%
结果以均值±标准误表示,统计学分析采用SigmaStat软件对数据进行重复测定双因素方差分析,组间比较采用SNK检验。P<0.05被认为具有统计学差异。
试验结果如表1所示。
表1-实施例1、2、3及实施例4对甲醛所致小鼠舔舐时间的影响(n=10,单位:s)
*P<0.05,与模型组相比;**P<0.01,与模型组相比;***p<0.001,与模型组相比。
由上表结果说明,与模型组小鼠相比,在注射甲醛0~5分钟,双氯芬酸钠组舔舐时间明显降低(P<0.01),0.1%豨莶提取物组、0.2%干姜提取物组和0.6%苦参提取物组的动物的舔舐时间明显降低(P<0.05),中、高剂量组的动物的舔舐时间分别明显降低(P<0.01)和非常明显降低(P<0.001)。
从上述结果可以得出以下结论:豨莶提取物、干姜提取物和苦参提取物都具有显著的镇痛作用,但豨莶提取物、干姜提取物和苦参提取物三者的药物组合的镇痛功效均比其提取物单体更显著。
实施例7
采用大鼠角叉菜胶模型分别研究实施例1~实施例3以及实施例4所述的豨莶提取物组、干姜提取物组、苦参提取物以及中药组合物膏剂的抗炎作用。
试验采用雄性SD大鼠,体重250~300g,随机分成8组,每组10只。
试验组与实施例6相同。
实验开始前,外用受试物和双氯芬酸钠涂抹于大鼠左后足,按摩1min帮助吸收,1小时后相同足跖皮下注射1%角叉菜胶0.1ml。模型组只做按摩不涂药,1小时后相同足跖皮下注射1%角叉菜胶0.1ml。分别在涂药前,注射角叉菜胶后1、2、3、4小时后用足容积测量仪测量鼠爪肿胀的体积。计算各时间点足跖肿胀率:足跖肿胀率(%)=(注射后体积—注射前体积)/注射前体积×100%
结果以均值±标准误表示,统计学分析采用SigmaStat软件对数据进行重复测定双因素方差分析,组间比较采用SNK检验。P<0.05被认为具有统计学差异。
试验结果如表2所示。
表2-实施例1、2、3及实施例4对角叉菜胶所致的足跖肿胀率的影响(n=10;单位:%)
*P<0.05,与模型组相比;**P<0.01,与模型组相比。
由上表结果说明,模型组大鼠左后足明显肿胀,厚度增加,两足差异较大。与模型组相比,双氯芬酸钠在注射角叉菜胶3h后,足肿胀体积显著降低(P<0.01),0.2%干姜提取物注射角叉菜胶3h后足肿胀体积显著降低(P<0.05),低、中、高剂量的本药物组动物注射角叉菜胶3h后足肿胀体积显著降低(P<0.05)。
从上述结果可以得出以下结论:豨莶提取物、干姜提取物和苦参提取物三者的药物组合的抗炎功效都比其提取物单体更显著。
实施例8
研究实施例4中所述中药组合物的膏剂对炎性细胞浸润和炎症相关标记物表达水平的影响。
(1)将实施例7中的SD大鼠脚垫组织经4%甲醛溶液固定后,行石蜡包埋,切片(片厚4μm),切片经脱蜡、水化等步骤,进行HE染色。在普通光学显微镜下观察并拍照(20×物镜)。应用Photoshop7.0对真皮乳头层区域进行细胞计数,并比较每平方厘米区域内细胞的个数,得到炎性细胞浸润情况,其结果如表3所示。
(2)将实施例7中的SD大鼠脚垫组织在低温环境下剪碎,并置于RIPA缓冲液中超声匀浆,然后在12000rpm离心,并收集上清。BCA法测定蛋白浓度,并按照ELISA试剂盒说明书进行相关指标检测,其结果如表4所示。
结果以均值±标准误表示,统计学分析采用SigmaStat软件对数据进行重复测定双因素方差分析,组间比较采用SNK检验。P<0.05被认为具有统计学差异。
表3-实施例4对大鼠脚底注射角叉菜胶后脚垫组织炎性细胞浸润的影响(n=10)
组别 | 细胞数目(/cm2) |
模型组 | 7.2±0.8 |
双氯芬酸钠 | 3.7±0.3** |
低剂量组 | 4.9±0.6* |
中剂量组 | 4.5±0.4* |
高剂量组 | 4.0±0.5* |
*P<0.05,与模型组相比;**P<0.01,与模型组相比。
表4-实施例4对大鼠脚底注射角叉菜胶后炎症相关标记物表达水平的影响(n=10/组)
*P<0.05,与模型组相比;**P<0.01,与模型组相比。
根据表3可以得出以下结论:与模型组相比,低、中、高剂量的药物组合具有显著抑制炎性细胞浸润的作用(P<0.05),双氯芬酸钠能更显著的抑制炎性细胞的浸润(P<0.01)。
根据表4可以得出以下结论:低、中、高剂量的药物组合对炎症相关标记物IL-1β、TNF-α、COX2和NF-κB均有显著性影响(P<0.01),但双氯芬酸钠没有对这些炎症相关标记物的表达产生显著的影响。
实施例9
对实施例4中所述的中药组合物膏剂进行安全性测试。
所述安全性测试包括小鼠急性经口毒性实验、豚鼠经皮毒性实验、多次皮肤刺激性实验、皮肤变态反应实验,实验设计完全遵循《化妆品卫生规范(2007年版)》。结果表明,小鼠在给予5g/kg受试品后没有明显皮肤粘膜及呼吸的异常,并且活动度良好,没有动物死亡,在染毒后的14天内动物体重稳定增加。豚鼠在涂抹2g/kg受试品后没有明显皮肤粘膜及呼吸的异常,并且活动度良好,没有动物死亡,在染毒后的14天内动物体重稳定增加。家兔每天涂抹0.5mL受试物,共涂14天,在此期间,家兔皮肤没有红斑和水肿现象,受试物对家兔的皮肤无刺激性。豚鼠局部封闭涂皮实验,豚鼠无红斑和水肿现象,受试物对豚鼠的皮肤无致敏性。上述结果均表明:受试物无明显的毒副作用。
实施例10
王某,男,28岁,颈肩疼痛1周,按压有明显刺痛,头部旋转、伸屈能力受限。采用实施例5贴剂对疼痛部位进行干预半小时,对干预前后疼痛部位肌肉活动度进行评价。结果发现,疼痛程度(Visual Analogue Scale,VAS)和颈部失能指数(Neck Disability Index,NDI)都明显降低,关节活动度(Active Range of Motion,AROM)得到改善,即头部旋转范围、伸屈程度都明显增加。
由上述实施例可知,本发明所述的消炎镇痛中药组合物及其膏剂,其可用于肌肉、骨骼的消炎镇痛,能显著减少福尔马林疼痛模型小鼠舔后足的次数,具有镇痛作用;同时显著下调模型个体IL-1β、TNF-α、COX2和NF-κB的表达,抑制炎症细胞的浸润,缓解局部炎症;本发明所述的含有豨莶提取物、干姜提取物、苦参提取物的中药组合物配伍精当,见效较快,且安全无毒副作用。
以上对本发明的具体实施例进行了详细描述,但其只作为范例,本发明并不限制于以上描述的具体实施例。对于本领域技术人员而言,任何对该实用进行的等同修改和替代也都在本发明的范畴之中。因此,在不脱离本发明的精神和范围下所作的均等变换和修改,都应涵盖在本发明的范围内。
Claims (10)
1.一种消炎镇痛中药组合物,其特征在于,包括豨莶提取物、干姜提取物和苦参提取物,所述豨莶提取物、干姜提取物和苦参提取物的重量比为1~4:2~5:6~10。
2.一种如权利要求1所述的消炎镇痛中药组合物的制备方法,其特征在于,包括如下步骤:
步骤一、分别制备豨莶提取物、干姜提取物、苦参提取物;
步骤二、将水、增稠剂、液体防腐剂混合得到A相;
步骤三、在丁二醇中添加豨莶提取物、干姜提取物、苦参提取物得到B相;
步骤四、将步骤三所述的B相溶于步骤二所述的A相,得到C混合相;
步骤五、在步骤四所述的C混合相中加入润肤剂和油脂,得到D混合相;
步骤六、在步骤五所述的D混合相中加入PH调节剂调节PH值,充分搅拌,制得中药组合物膏剂。
3.根据权利要求2所述的消炎镇痛中药组合物的制备方法,其特征在于,在所述步骤六中制备的中药组合物膏剂中,以重量计,豨莶提取物的含量为0.1%~0.4%,干姜提取物的含量为0.2%~0.5%,苦参提取的含量为0.6%~1.0%。
4.根据权利要求2所述的消炎镇痛中药组合物的制备方法,其特征在于,所述豨莶提取物的制备方法如下:
将豨莶草粉碎、过筛,加入溶剂进行水浴提取,提取液静置过夜;对提取液进行抽滤,将所得的滤液进行富集纯化、旋蒸干燥,获得豨莶提取物。
5.根据权利要求4所述的消炎镇痛中药组合物的制备方法,其特征在于,所述溶剂为水,所述水浴提取次数为2次,所述水浴的温度为50℃,所述提取液采用乙醇洗脱、过树脂柱进行富集纯化。
6.根据权利要求2所述的消炎镇痛中药组合物的制备方法,其特征在于,所述干姜提取物的制备方法如下:干姜片粉碎、过筛,加入70%乙醇水溶液进行超声提取,对提取液进行抽滤,将所得的滤液干燥,获得干姜提取物。
7.根据权利要求2所述的消炎镇痛中药组合物的制备方法,其特征在于,所述苦参提取物的制备方法如下:苦参粉碎、过筛,加入水,进行回流提取;对提取液进行抽滤,将所得的滤液干燥,获得苦参提取物。
8.根据权利要求7所述的消炎镇痛中药组合物的制备方法,其特征在于,所述回流提取的次数为3次,每次回流提取的时间为3小时。
9.根据权利要求2所述的消炎镇痛中药组合物的制备方法,其特征在于,所述增稠剂为卡波姆U21,所述液体防腐剂为PE9010,所述润肤剂为异壬酸异壬酯,所述油脂为GTCC,所述PH调节剂为1%氢氧化钠,所述PH值为5.5~6.5。
10.一种如权利要求1所述的消炎镇痛中药组合物在药品和日化产品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610975919.1A CN106267134A (zh) | 2016-11-07 | 2016-11-07 | 一种消炎镇痛中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610975919.1A CN106267134A (zh) | 2016-11-07 | 2016-11-07 | 一种消炎镇痛中药组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106267134A true CN106267134A (zh) | 2017-01-04 |
Family
ID=57720977
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610975919.1A Pending CN106267134A (zh) | 2016-11-07 | 2016-11-07 | 一种消炎镇痛中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106267134A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109303743A (zh) * | 2018-11-21 | 2019-02-05 | 柳州两面针股份有限公司 | 中药组合物在制备护肤品中的应用 |
-
2016
- 2016-11-07 CN CN201610975919.1A patent/CN106267134A/zh active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109303743A (zh) * | 2018-11-21 | 2019-02-05 | 柳州两面针股份有限公司 | 中药组合物在制备护肤品中的应用 |
CN109303743B (zh) * | 2018-11-21 | 2021-05-25 | 柳州两面针股份有限公司 | 中药组合物在制备护肤品中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080220084A1 (en) | Combination therapy for alleviating pain-related conditions | |
CN100542585C (zh) | 一种具有镇痛和抗炎作用的外用药物组合物 | |
CN103169928B (zh) | 治疗痛经的外用中药组合物及其制备方法和应用 | |
CN106421663A (zh) | 一种治疗风湿骨病的药物组合物及其制备方法 | |
CN101214286A (zh) | 一种有效治疗风湿性疼痛病的中药白酒制剂 | |
CN1824009B (zh) | 一种可内外服用的多用途药物组合物 | |
CN103520572A (zh) | 一种用于治疗特应性皮炎的中药组合物及其制备方法 | |
CN102380015B (zh) | 治疗类风湿性关节炎的药物组合物及其制备方法和用途 | |
CN104689226A (zh) | 一种治疗小儿类风湿性关节炎的中药组合物及其制备方法 | |
CN101028376A (zh) | 一种治疗习惯性流产的中药制剂 | |
CN103751734B (zh) | 活血止痛巴布膏及其制备方法 | |
CN101167937A (zh) | 一种治疗风湿或类风湿的中药组合物贴膏及其制备方法 | |
CN102671178B (zh) | 一种治疗肾病综合症及尿毒症的中药组合物配制方法及应用 | |
CN102038778B (zh) | 一种舒经活络、祛风除湿的中药组合物及其制备方法 | |
CN108210584A (zh) | 消炎止痛快速愈合外用中药制剂及其制备方法 | |
CN101181499A (zh) | 治疗痤疮的药物组合物、其制剂和制备方法 | |
CN101057922B (zh) | 一种治疗白癜风病的中药制剂 | |
CN100450517C (zh) | 一种治疗妇女痛经的中药制剂 | |
CN106620541B (zh) | 一种治疗慢性湿疹的外用中药组合物及其制备方法 | |
CN106267134A (zh) | 一种消炎镇痛中药组合物及其制备方法 | |
CN103083488B (zh) | 一种用于治疗骨病的中药组合物及其制剂 | |
CN110302336A (zh) | 预防脑卒中后肩手综合征的中药组合物及其制备方法与应用 | |
CN101337026A (zh) | 一种治疗痛风的外用药物组合物 | |
TWI409076B (zh) | 用於消炎消腫止痛之中草藥組成物、製備方法及其應用 | |
CN111991527A (zh) | 足药浴配方及其制备工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170104 |
|
RJ01 | Rejection of invention patent application after publication |